The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Open accessAbstract
Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) are agents currently in clinical use for nonmalignant conditions. We report the use of PDE5 inhibitors as modulators of the antitumor immune response. In several mouse tumor models, PDE5 inhibition reverses tumor-induced immunosuppressive mechanisms and enables a measurable antitumor immune response to be generated that substantially delays tumor progression. In particular, sildenafil, down-regulates arginase 1 and nitric oxide synthase–2 expression, thereby reducing the suppressive machinery of CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs) recruited by growing tumors. By removing these tumor escape mechanisms, sildenafil enhances intratumoral T cell infiltration and activation, reduces tumor outgrowth, and improves the antitumor efficacy of adoptive T cell therapy. Sildenafil also restores in vitro T cell proliferation of peripheral blood mononuclear cells from multiple myeloma and head and neck cancer patients. In light of the recent data that enzymes mediating MDSC-dependent immunosuppression in mice are active also in humans, these findings demonstrate a potentially novel use of PDE5 inhibitors as adjuncts to tumor-specific immune therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“A direct correlation exists between the number of tumor-infi ltrating lymphocytes (TILs) and a favorable clinical outcome, as demonstrated in patients with metastatic ovarian cancer (20).”
BackgroundIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., & Ohtani, H. (1998) · PubMed · Cited by 1,193
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Mechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Takimoto, E., Champion, H. C., Li, M., Belardi, D., Ren, S., Rodriguez, E. R., Bedja, D., Gabrielson, K. L., Wang, Y., & Kass, D. A. (2005) · Nature Medicine · doi:10.1038/nm1175 · Cited by 903
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
Self-citationSERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Self-citationInduction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 704
Self-citationMyeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
Self-citationL-arginine metabolism in myeloid cells controls T-lymphocyte functions
Bronte, V., Serafini, P., Mazzoni, A., Segal, D. M., & Zanovello, P. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00132-7 · Cited by 592
Self-citationTerabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice
Bronte, V., Serafini, P., De Santo, C., Marigo, I., Tosello, V., Mazzoni, A., Segal, D. M., Staib, C., Lowel, M., Sutter, G., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.270 · Cited by 513
Self-citationCyclic nucleotide phosphodiesterases
Essayan, D. M. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.119555 · Cited by 503
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Schumacher, K., Haensch, W., Röefzaad, C., & Schlag, P. M. (2001) · PubMed · Cited by 503
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
Bronte, V., Kasic, T., Gri, G., Gallana, K., Borsellino, G., Marigo, I., Battistini, L., Iafrate, M., Prayer-Galetti, T., Pagano, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042028 · Cited by 396
Self-citationHuang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9730 · Cited by 388
Lin, H.-H., Faunce, D. E., Stacey, M., Terajewicz, A., Nakamura, T., Zhang-Hoover, J., Kerley, M., Mucenski, M. L., Gordon, S., & Stein-Streilein, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042307 · Cited by 385
TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response
Baniyash, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1434 · Cited by 344
Inhibition of tumor growth by elimination of granulocytes.
Pekarek, L. A., Starr, B. A., Toledano, A. Y., & Schreiber, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.435 · Cited by 340
Mihm, M. C., Clemente, C. G., & Cascinelli, N. (1996) · PubMed · Cited by 318
Bronte, V., Wang, M., Overwijk, W. W., Surman, D. R., Pericle, F., Rosenberg, S. A., & Restifo, N. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5313 · Cited by 312
Self-citationPhosphodiesterase 5 inhibitors: current status and potential applications
Rotella, D. P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd893 · Cited by 306
De Santo, C., Serafini, P., Marigo, I., Dolcetti, L., Bolla, M., Del Soldato, P., Melani, C., Guiducci, C., Colombo, M. P., Iezzi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409783102 · Cited by 284
Self-citationRegulation of Gene Expression by Cyclic GMP
Pilz, R. B., & Casteel, D. E. (2003) · Circulation Research · doi:10.1161/01.res.0000103311.52853.48 · Cited by 280
Pak, A. S., Wright, M. A., Matthews, J. P., Collins, S. L., Petruzzelli, G. J., & Young, M. R. I. (1995) · PubMed · Cited by 271
In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2
(1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/79.5.1067 · Cited by 258
Vesalainen, S., Lipponen, P., Talja, M., & Syrjänen, K. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)e0159-2 · Cited by 254
Enhancer-Mediated Control of Macrophage-Specific Arginase I Expression
Pauleau, A.-L., Rutschman, R., Lang, R., Pernis, A., Watowich, S. S., & Murray, P. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7565 · Cited by 243
TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma
Nanni, P., De Giovanni, C., Lollini, P.-L., Nicoletti, G., & Prodi, G. (1983) · Clinical & Experimental Metastasis · doi:10.1007/bf00121199 · Cited by 226
Hung, A. C. F. (1996) · Medical Entomology and Zoology · Cited by 206
Webb, B. L. J., Hirst, S. J., & Giembycz, M. A. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703452 · Cited by 178
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.
Seung, L. P., Rowley, D. A., Dubey, P., & Schreiber, H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6254 · Cited by 170
Haanen, J. B. A. G., Baars, A., Gomez, R., Weder, P., Smits, M., de Gruijl, T. D., Blomberg, B. M. E. V., Bloemena, E., Scheper, R. J., van Ham, S. M., et al. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0018-5 · Cited by 152
Sarfati, M., Mateo, V., Baudet, S., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0075 · Cited by 142
Saparov, A., Wagner, F. H., Zheng, R., Oliver, J. R., Maeda, H., Hockett, R. D., & Weaver, C. T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80102-8 · Cited by 100
Young, M. R., Wright, M. A., & Pandit, R. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.2.990 · Cited by 88
Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
Setter, S. M., Iltz, J. L., Fincham, J. E., Campbell, R. K., & Baker, D. E. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e487 · Cited by 84
Safeguarding Patients in Clinical Trials with High Mortality Rates
Freeman, B. D., Danner, R. L., BANKS, S. M., & Natanson, C. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.2.2011028 · Cited by 69
Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer
Wang, R. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.009 · Cited by 65
Sildenafil for Pulmonary Hypertension
Lee, A. J., Chiao, T. B., & Tsang, M. P. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e426 · Cited by 64
Lin, C., Chow, S., Lau, A., Tu, R., & Lue, T. F. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4221 · Cited by 54
van Oijen, M., Bins, A. D., Elias, S. G., Sein, J. J., Weder, P., GAST, G. C. D., Mallo, H. A., Gallee, M. P. W., van Tinteren, H., Schumacher, T. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0260 · Cited by 52
Suzue, K., Reinherz, E., & Koyasu, S. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3147::aid-immu3147>3.0.co;2-f · Cited by 43
Chemotherapy of large intestinal carcinoma. Current results and future prospects
Schein, P. S., Kisner, D. L., & Macdonald, J. S. (2006) · Cancer · doi:10.1002/1097-0142(197512)36:6<2441::aid-cncr2820360627>3.0.co;2-p · Cited by 19
Cited by
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationInflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Metadata
- Authors
- Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-11-13
- Volume
- 203
- Issue
- 12
- Pages
- 2691-2702
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2120539661
- Cited by
- 766
- References
- 53
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.